A J Kraker

1.0k total citations
18 papers, 879 citations indexed

About

A J Kraker is a scholar working on Oncology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, A J Kraker has authored 18 papers receiving a total of 879 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Organic Chemistry and 6 papers in Molecular Biology. Recurrent topics in A J Kraker's work include Synthesis and biological activity (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Trace Elements in Health (4 papers). A J Kraker is often cited by papers focused on Synthesis and biological activity (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Trace Elements in Health (4 papers). A J Kraker collaborates with scholars based in United States and New Zealand. A J Kraker's co-authors include David H. Petering, Charles Watson Moore, C. Frank Shaw, Richard Jove, Jie Wu, David W. Fry, William A. Denny, Jay F. Dorsey, Andrew M. Thompson and Alexander J. Bridges and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Biochemical and Biophysical Research Communications.

In The Last Decade

A J Kraker

18 papers receiving 835 citations

Peers

Countries citing papers authored by A J Kraker

Since Specialization

Citations

This map shows the geographic impact of A J Kraker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A J Kraker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A J Kraker more than expected).

Fields of papers citing papers by A J Kraker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A J Kraker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A J Kraker. The network helps show where A J Kraker may publish in the future.

Co-authorship network of co-authors of A J Kraker

This figure shows the co-authorship network connecting the top 25 collaborators of A J Kraker. A scholar is included among the top collaborators of A J Kraker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A J Kraker. A J Kraker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	53 Pyrrolo[3,4-c]carbazole-1,3-dione inhibitors of the G2/M checkpoint kinase wee1 2004 ·European Journal of Cancer Supplements ·Brian D. Palmer, R J Booth, William A. Denny, Kenneth E. Hook, A J Kraker, (unknown), Daniel F. Ortwine, Jeff B. Smaill, C.J. Squire, Andrew M. Thompson	1
2	Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors 2002 ·Leukemia ·(unknown), (unknown), (unknown), Mei Huang, A J Kraker, Kapil N. Bhalla, Richard Jove, Jie Wu	41
3	The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. 2000 ·PubMed ·Jay F. Dorsey, Richard Jove, A J Kraker, Jie Wu	130
4	Discovery of a novel abl tyrosine kinase inhibitor that selectively induces apoptosis of bcr-abl-positive leukemic cells 2000 ·Experimental Hematology ·Jay F. Dorsey, Richard Jove, A J Kraker, Jie Wu	2
5	Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth 1999 ·Leukemia ·Vera Roginskaya, (unknown), Eva G. Caudell, (unknown), A J Kraker, (unknown)	79
6	1-Oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase 1997 ·Bioorganic & Medicinal Chemistry Letters ·Mark R. Barvian, Robert L. Panek, Gina H. Lu, A J Kraker, Aneesa M. Amar, Brian G. Hartl, James M. Hamby, H. D. Hollis Showalter	11
7	Inhibition of Growth Factor-Mediated Tyrosine Phosphorylation in Vascular Smooth Muscle by PD 089828, a New Synthetic Protein Tyrosine Kinase Inhibitor 1997 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), Gina H. Lu, James M. Hamby, Brian L. Batley, A J Kraker, Robert L. Panek	23
8	Tyrosine kinase inhibitors. 7. 7-amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor 1995 ·Journal of Medicinal Chemistry ·Andrew M. Thompson, Alexander J. Bridges, David W. Fry, A J Kraker, William A. Denny	127
9	Tyrosine kinase inhibitors. 2. Synthesis of 2,2'-dithiobis(1H-indole-3-alkanamides) and investigation of their inhibitory activity against epidermal growth factor receptor and pp60v-src protein tyrosine kinases 1994 ·Journal of Medicinal Chemistry ·Andrew M. Thompson, David W. Fry, A J Kraker, William A. Denny	23
10	Tyrosine Kinase Inhibitors. 3. Structure-Activity Relationships for Inhibition of Protein Tyrosine Kinases by Nuclear-Substituted Derivatives of 2,2'-Dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide) 1994 ·Journal of Medicinal Chemistry ·Gordon W. Rewcastle, Brian D. Palmer, Ellen M. Dobrusin, David W. Fry, A J Kraker, William A. Denny	28
11	ChemInform Abstract: Tyrosine Kinase Inhibitors. Part 2. Synthesis of 2,2′‐Dithiobis(1H‐ indole‐3‐alkanamides) and Investigation of Their Inhibitory Activity Against Epidermal Growth Factor (EGF) Receptor and pp60v‐src Protein Tyrosine Kinases. 1994 ·ChemInform ·Andrew M. Thompson, David W. Fry, A J Kraker, William A. Denny	3
12	Pentostatin: future directions. 1992 ·Pharmacological Reviews ·Wayne D. Klohs, A J Kraker	20
13	Chemistry, cytotoxicity, and DNA-binding of bis-platinum complexes 1989 ·Journal of Inorganic Biochemistry ·A J Kraker, (unknown), (unknown), Nicholas P. Farrell, James D. Hoeschele, John D. Roberts	7
14	Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. 1988 ·PubMed ·A J Kraker, Charles Watson Moore	102
15	Zinc metabolism in Ehrlich cells: properties of a metallothionein-like zinc-binding protein. 1988 ·PubMed ·A J Kraker, Glenn R. Krakower, C. Frank Shaw, David H. Petering, Justine S. Garvey	25
16	Binding of cis-dichlorodiammine platinum(II) to metallothionein in Ehrlich cells 1985 ·Biochemical and Biophysical Research Communications ·A J Kraker, James J. Schmidt, Susan Krezoski, David H. Petering	51
17	Reaction of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) Cu(II) with Ehrlich cells. Binding of copper to metallothionein and its relationship to zinc metabolism and cell proliferation. 1985 ·Journal of Biological Chemistry ·A J Kraker, Susan Krezoski, Jeffrey A. Schneider, Daniel T. Minkel, David H. Petering	51
18	Ligand substitution reactions of metallothioneins with EDTA and apo-carbonic anhydrase. 1980 ·Proceedings of the National Academy of Sciences ·(unknown), A J Kraker, C. Frank Shaw, David H. Petering	155

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact